ABBOTT LABORATORIES
Income flow
Annual
ABT 10-K Income StatementPeriod 2025-12-31Source 10-K
As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.
Revenue mix
2025-12-31 · 10-K · USD
By activity
- Medical Devices$21.4B48.3%
- Diagnostic Products$8.9B20.2%
- Nutritional Products$8.5B19.1%
- Established Pharmaceutical Products$5.5B12.5%
By geography
- Non-US$27.2B38.0%
- United States$17.1B23.9%
- All Other Countries$16.0B22.3%
- DE$2.8B3.9%
- CN$1.9B2.7%
- CH$1.9B2.6%
- IN$1.9B2.6%
- JP$1.5B2.1%
- GB$1.3B1.9%
Capital & dividends
YieldTrailing twelve-month dividends as a percent of the current share price (income yield).2.46%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.1.85%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).2.48PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.78.7%Shares outTotal shares currently outstanding (issued and not retired).1.74BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).1.72B
Upcoming dividend
- Next ex-div
- 2026-10-15 · declared
- Next pay
- 2026-11-16
- Last cash
- 0.63 · 2026-07-15
Annual DPS
1.2819
1.4420
1.821
1.8822
2.0423
2.224
2.3625
1.8926
Shares outstanding (as-filed)
1.79B21
1.76B22
1.75B23
1.75B24
1.75B25
Stock splits
- 10000:47982013-01-02
Recent payments
0.4710/22
0.5101/23
0.5104/23
0.5107/23
0.5110/23
0.5501/24
0.5504/24
0.5507/24
0.5510/24
0.5901/25
0.5904/25
0.5907/25
0.5910/25
0.6301/26
0.6304/26
0.6307/26
Valuation
Trailing PE 33.1 (2025-12-31)
Fiscal PE5
| Period | EPS | Close | PE |
|---|---|---|---|
| 2025-12-31 | 3.72 | 123 | 33.1 |
| 2024-12-31 | 7.64 | 108.98 | 14.3 |
| 2023-12-31 | 3.26 | 103.98 | 31.9 |
| 2022-12-31 | 3.91 | 101.68 | 26.0 |
| 2021-12-31 | 3.94 | 128.19 | 32.5 |
PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.